

20 Nov 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by

In this week's podcast edition of Five Must-Know Things: a market snapshot of inflammatory bowel disease; will biotech bounce back in 2023?; Phase III miss for Roche's Alzheimer's candidate; how Japan's top firms did in the quarter; and China showcase hints at policies and strategies.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 18 November 2022, including: a market snapshot of inflammatory bowel disease; will biotech bounce back in 2023?; Phase III miss for [*Roche Holding AG*](#)'s Alzheimer's candidate; how Japan's top firms did in the quarter; and China showcase hints at policies and strategies.

This and all our other podcasts are available on the Pharma Intelligence channel on [*Apple Podcasts*](#), [*Google Podcasts*](#), [*SoundCloud*](#), [*TuneIn*](#) and [*Spotify Podcasts*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[*IBD Market Snapshot: Changes Ahead, But Current Biologics Are Formidable Competitors*](#)" - Scrip, 11 Nov, 2022.)

(Also see "[*After Cutting Back And Clinging On, Will Biotech Bounce Back In 2023?*](#)" - Scrip, 16 Nov, 2022.)

(Also see "[*Roche's Alzheimer's Drug Fails In Phase III Giving Eisai/Biogen A Clear Run*](#)" - Scrip, 14 Nov, 2022.)

(Also see "[*Japan Q2 Roundup: Mixed Bag For Majors But Forex Provides Boost*](#)" - Scrip, 10 Nov, 2022.)

(Also see "[*Show Me CIIE: Can Foreign Pharma Continue Growth Trajectory In Closing China?*](#)" - Scrip, 10 Nov, 2022.)

[Click here to explore this interactive content online](#) ✨